Previous work has shown that treatment with thyroid hormone (T3) decreased the incidence of rat hepatocellular carcinoma (HCC). The present study was designed to determine whether the inhibitory effect of T3 on HCC development was limited to early steps of the carcinogenetic process or, whether a similar effect could also be exerted by starting T3 treatment at later stages. Hepatic nodules were induced in Fischer rats by a single dose of DENA, followed by a 2-week exposure of the animals to 2-AAF and partial hepatectomy. Rats were then divided into 3 groups: group 1 was maintained on basal diet; group 2 was fed a diet containing 4 mg/kg T3 for a week, every month/7 months, starting 9 weeks after DENA administration; group 3 was exposed to cycles of T3 starting 8 months after initiation. Results demonstrate that inhibition of HCC development was essentially similar in rats exposed to T3 starting either 9 weeks or 8 months after initiation (50% inhibition compared to control rats). We have previously shown that T3-induced nodule regression and HCC inhibition occurred in spite of its mitogenic effect. Therefore, we next wished to determine whether a similar antitumoral effect could be exerted by other liver mitogens, such as peroxisome proliferators. Rats exposed to the initiation-promotion protocol described previously, were subjected to 11 cycles of a T3 or a ciprofibrate-supplemented diet, each cycle consisting of 7 days/month; the incidence of HCC and lung metastases was determined 13.5 months after initiation. Results showed that although treatment with T3 strongly inhibited HCC development (only 31% of T3 + rats showed HCC vs 91% of controls), rats given ciprofibrate developed the same number of HCC as T3-untreated rats. In conclusion, the results of this study showed that the anticarcinogenic effect of T3 is maintained also when treatment begins late in the process, and its antitumoral property appears to be specific and may not be shared by other liver mitogens.
INTRODUCTION
Adult liver is a quiescent organ exhibiting minimal replicative capacity and, in fact, mitosis is observed only in approximately 1 in every 20,000 hepatocytes (29) . However, hepatocytes begin to proliferate in a relatively synchronized manner in response to a reduction in liver mass caused by partial surgical removal of the liver or after chemical, nutritional, vascular, and viruses-induced liver injury (compensatory regeneration or compensatory hyperplasia). Several lines of evidence suggest that conditions characterized by liver damage and enhanced hepatocyte turnover are associated with an increased incidence of HCC in humans as well as experimental animals (12, 31, 36) . Risk factors include chronic infection with hepatitis B virus (HBV) and hepatitis C virus (HCV), aflatoxin B1, hemochromatosis, alcohol etc (3, 18, 19, 25, 36) . All these evidences have led to the hypothesis (1, 9), although controversial (22, 28, 37) , that cell proliferation per se may be carcinogenic and carcinogens that increase cell proliferation may be operating exclusively by this mechanisms. On the other hand, hepatocyte proliferation induced by agents that induce hepatocyte proliferation without causing cell death (primary mitogens), unlike liver regeneration following two thirds partial hepatectomy or necrogenic compounds, does not support initiation of chemical hepatocarcinogenesis (11) .
As to the promotion phase of hepatocarcinogenesis, it was shown that while chronic exposure to xenobiotics such as peroxisome proliferators (PPs) is carcinogenic in rodent liver (7, 17, 32) , short term exposure to the PP ciprofibrate, which is associated with a strong increase in hepatocyte proliferation, resulted in the inhibition of DNA synthesis of preneoplastic hepatocytes and a rapid decrease in area and number of γ -glutamyl transpeptidase-positive hyperplastic hepatic nodules (8) . Moreover, hepatocyte proliferation induced by thyroid hormone (T3) did not induce the growth of carcinogeninitiated cells (23) , inhibited the promoting ability of 2-AAF (23), and induced a rapid regression of carcinogen-induced hepatic nodules and reduced the incidence of HCC and lung metastasis, in spite of its strong mitogenic effect on both normal and nodule hepatocytes (24) . These findings raise the important issue as to whether induction of liver cell proliferation is always a promoting condition for carcinogen-initiated cells, or whether the nature of the proliferative stimulus is important in determining the type of response of carcinogen altered cells. The hormone T3 resembles PPs in that it is a ligand of a nuclear receptor (TRs) of the same superfamily of steroid hormone nuclear receptors (20, 26) ; it is an inducer of peroxisome proliferation (16) ; and it is a potent hepatomitogen (15, 30, 33) .
Although repeated treatment with T3 appears to play an antipromoting effect on HCC development, the effect of hepatocyte proliferation induced by PPs on progression of hyperplastic nodules generated by genotoxic carcinogens remains unclear. To further investigate the effect of 114 LEDDA-COLUMBANO ET AL TOXICOLOGIC PATHOLOGY hepatocyte proliferation induced by primary mitogens on the growth of carcinogen-induced lesions, we have examined and compared the effect of T3 and Ciprofibrate on the progression of hepatic nodules, induced in rats by the R-H model, to hepatocellular carcinomas. Another important issue raised in the present study was whether the antipromoting effect of T3 could be exerted only when treatment was applied at very early stages of the carcinogenic process or whether beginning of T3 treatment at late stages could still inhibit HCC development.
MATERIALS AND METHODS

Animals:
Male Fischer F-344 (100-125 g) purchased from Charles River, Milano, Italy, were maintained on a laboratory diet (Ditta Mucedola, Milano, Italy). The ani-FIGURE 1.-Schematic representation of the experimental protocol 1. Rats were injected intraperitoneally with a single dose of DENA (150 mg/Kg). After 2 weeks, rats were placed on a diet containing 0.02% 2-AAF for 2 weeks, and after the first week were subjected to 2/3 partial hepatectomy. Five weeks or eight months after the end of 2-AAF feeding, rats were exposed to 7 or 5 cycles of a diet containing 4 mg/kg of T3 (each cycle 1 week/month) or were maintained on a basal diet. All animals were sacrificed 13.5 months after initiation. mals were given food and water ad libitum with a 12-hour light/dark daily cycle and were acclimatized for 1 week before the start of the experiment. Guidelines for the Care and Use of Laboratory Animals were followed during the investigation. Diethylnitrosamine, 3,5,3 -triiodo-L-thyronine, and 2-acetylaminofluorene were purchased from Sigma (Sigma Chem Co, St Louis, MO). Ciprofibrate (CIPRO) was a kind gift from Sanofi Winthrop (Guilford, UK).
Experimental Protocol I (Figure 1 ): Rats were injected intraperitoneally with a single dose of diethylnitrosamine (DENA), dissolved in saline, at the dose of 150 mg/kg body weight. Following a 2-week recovery period, rats were exposed to the R-H model (34) consisting of feeding rats a diet containing 0.02% 2-acetylaminofluorene (2-AAF) for 1 week; rats were then subjected to a standard two-thirds partial hepatectomy (PH), and continued for an additional Vol. 31, No. 1, 2003 EFFECT OF T3 ON RAT LIVER CANCER DEVELOPMENT 115 week on the 2-AAF containing diet. Rats were then returned to the basal diet for 5 weeks and then divided into 3 groups; the first group was maintained on a basal diet all throughout the experiment; group 2 was exposed to 7 cycles of a diet containing 4 mg/kg of T3, each cycle being 7 days/month; group 3 was exposed to the same initiation-promotion protocol, but T3 treatment started only 8 months after initiation and for only 5 cycles. All groups were sacrificed 13.5 months after initiation and the incidence of HCC and lung metastasis was determined.
Experimental Protocol II ( Figure 2 ): Nine weeks after treatment with DENA, rats subjected to the initiationpromotion assay described in experiment 1, were either main-FIGURE 2.-Schematic representation of the experimental protocol 2. Rats were subjected to the initiation-promotion regimen as described in experimental protocol 1. Five weeks after release from 2-AAF diet, rats were either maintained on a basal diet or exposed to eleven cycles of T3-or a CIPRO-supplemented diet. Rats were then placed on a basal diet and sacrificed 13.5 months after initiation. tained on a basal diet or exposed to 11 cycles of a diet supplemented with 4 mg/kg of T3 or 0.025% CIPRO, each cycle being 7 days/month, for 1 week. Rats were sacrificed 13.5 months after DENA treatment and incidence of HCC development and lung metastasis was determined.
Effect of CIPRO on GSTP-Positive Liver Nodules: Nine weeks after treatment with DENA, rats subjected to the initiation-promotion assay described in experiment 1 were fed a CIPRO-supplemented diet (0.025%) for 1 week and sacrificed on day 7.
Histology and Immunohistochemistry: Immediately after sacrifice, liver sections were fixed in 10% formalin, embedded in paraffin, and routinely stained with hematoxylin-eosin. 
Statistical Analysis:
Comparison between treated and control group was performed by Student's t-test.
RESULTS AND DISCUSSION
Effect of Early and Late Treatment with T3 on HCC Development
Macroscopically, no tumors could be observed in untreated rats or in animals treated with DENA alone (data not shown). Almost all rats exposed to the complete R-H protocol (DENA + AAF + PH) showed multiple tumors ( Figure 3A) . On the contrary, 5/10 rats exposed to 7 cycles of T3 starting 5 weeks after 2-AAF release (group 2) did not show evidence of tumors. In contrast to the T3-untreated group, a single clearly defined tumoral mass was generally observed in these animals ( Figure 3B ). Histologic observation confirmed the presence of tumors in 10/11 rats exposed to DENA + AAF + PH in the absence of T3 (Table 1) , and revealed that all tumors in this group were classical trabecular hepatocellular carcinomas (see Figure 3C ), yet tumors seen in DENA + AAF + PH + T3 group were frequently adenocarcinomas (See Figure 3D ) with cystic or papillary cystic patterns. Moreover, in the DENA + AAF + PH group, metastases to the lung were found in 4 out of 11 animals (36%) (see Table 1 ); only 1 metastasis was found in T3-exposed animals (10%). These results are in agreement with previously published reports (24) .
As shown in Table 1 , beginning of T3 treatment 8 months after DENA initiation was still able to cause a strong reduction in the incidence of HCC development. Indeed, only 6/12 rats developed HCC (50% developed HCC vs 91% of rats treated with DENA + AAF + PH, in the absence of T3), indicating that the anticarcinogenic effect of T3 was maintained also when treatment was applied in animals bearing late-stage nodules.
Effect of T3 and CIPRO on Hepatocyte Proliferation
Previous studies have shown that 1 week's feeding of T3 was sufficient to induce a rapid regression of the great majority of GSTP-positive nodules (24) . Notably, the nodule regression occurred in spite of the powerful induction of hepatocyte proliferation caused by T3. Therefore, we wished to determine whether an accelerated regression of the nodules could also occur following treatment with the peroxisome proliferator ciprofibrate (CIPRO), that, similar to T3 is a ligand of steroid/thyroid nuclear receptors and a liver mitogen. Preliminary experiments were performed to determine the proliferative response of the liver to 1 week of treatment with CIPRO (0.025%). Hepatocytes were labeled with BrdU (1 mg/ml, dissolved in drinking water) all throughout the experimental period and rats were sacrificed on day 7. As shown in Figure 4 , while untreated liver exhibited a low labeling index (about 2%), CIPRO induced a strong increase in the proliferative capacity of hepatocytes which was comparable to that induced by T3. (LI was 8-and 11-fold higher than controls, respectively).
Effect of T3 and CIPRO on the Number and Size of GSTP-Positive Nodules
The latter studies showed that the mitogenic effect of CIPRO and T3 on normal hepatocyte was similar. Therefore, additional studies were performed to determine whether the effect of CIPRO on nodule regression could also be similar to that seen following T3 treatment. Rats initiated with DENA and subjected to the R-H model were fed CIPRO for 1 week. At the end of the week, rats were sacrificed and the number and size of the nodules was monitored. Livers from rats exposed to DENA + AAF + PH and sacrificed 6 weeks after release of 2-AAF showed the presence of several macroscopically evident, white nodules, merging from the surface. Immunohistochemically, 2 types of nodules could be easily identified: those characterized by a uniform GSTP staining and therefore classified as persistent nodules and those showing a progressive loss of GSTP staining (remodeling nodules) the total number of GSTP-positive nodules being 13 per cm 2 (see Table 2 ). Feeding CIPRO for 1 week did not cause any major change in the macroscopic appearance of the liver. Accordingly, quantification of the number of GSTP-positive nodules in CIPRO-treated rats did not show any significant reduction in their number, either considering the total number (10 GSTP-positive nodules/cm 2 vs 12.7 of controls) or the number of persistent nodules (2.29 vs 3.58). Moreover, no changes in the average size of the nodules or in the percent area occupied by GSTP-positive hepatocytes could be observed. These results clearly show that in spite of a similar effect on hepatocyte proliferation, CIPRO, unlike T3, does Rats initiated with DENA were then subjected to the R-H model to generate GSTPpositive hyperplastic nodules. Nine weeks or 8 months after DENA, rats were subjected to 7 or 5 cycles of T3, respectively. Rats were sacrificed 13.5 months after initiation.
not possess the capacity of inducing regression of hepatic nodules.
Effect of T3 and Ciprofibrate on the Incidence of Hepatocellular Carcinomas
We have previously shown that repeated cycles of T3 lead to reduction of HCC development (24) . Therefore, we next wished to determine whether repeated exposure to CIPRO could also lead to inhibition of HCC development. Similar to what is shown in Table 1 , almost all rats exposed to the complete R-H protocol (DENA + AAF +PH) showed multiple cancers. Histologic observation confirmed the presence of cancer in 10/11 rats exposed to DENA + AAF + PH in the absence of T3 (Table 3) . On the contrary, only 4/13 rats exposed to 11 cycles of T3 did show evidence of HCC (31%), with a percentage of lung metastasis that was only 8% vs 36% of controls. On the opposite, 11 cycles of CIPRO were completely ineffective in reducing the development of HCC. Indeed, 12/14 rats fed CIPRO for 11 cycles developed HCC (86%) vs 10/11 of controls (91%). Thus, despite the common mitogenic capacity, CIPRO, unlike T3, does not exert any anticarcinogenic affect on rat liver.
The results of the present study confirm our earlier observation that T3 treatment in the early stage of liver carcinogenesis inhibits HCC development, and extend further that similar inhibitory effects can be seen when T3 treatment was given during the late stage of carcinogenesis. The finding that FIGURE 4.-Labeling index of rat hepatocytes following one week exposure to a T3 or a CIPRO-supplemented diet. All rats were given BrdU (1 mg/ml) in drinking water for 7 days. At least 2,500 hepatocyte nuclei per rat were scored. LI was expressed as number of BrdU-positive hepatocyte nuclei/100 nuclei. Results are expressed as means ± SE of 4 to 5 animals per group. Significantly different from controls at p < 0.001. Rats initiated with DENA were then subjected to the R-H model to generate GSTPpositive hyperplastic nodules. Five weeks after 2-AAF release, rats were fed a diet supplemented with 0.025% CIPRO for 1 week.
* Mean ± SE of 6 animals/group. treatment with T3 is able to reduce the incidence of HCC also when administered 8 months after initiation of the carcinogenic process (corresponding to more than half of the total time required for HCC development), adds further strength to its potential therapeutic use in liver cancer prevention. Moreover, the fact that such inhibitory effect is obtained despite the strong mitogenic activity of thyroid hormone supports the notion that enhanced cell proliferation per se is not necessarily critical in progression of carcinogen-altered cells to HCC, but the nature of proliferative stimuli might be the important determinant in the process of HCC development. At present, it is not clear what is the mechanism responsible for the anticarcinogenic effect of T3. Previous studies (24) did not reveal any evidence of increased apoptosis in preneoplastic hepatocytes during T3 treatment; moreover, an increased proliferative activity was observed in nodules of rats treated with T3, thus ruling out the possibility that T3 can exert its anticarcinogenic effect by inhibiting preneoplastic cell growth. It is possible that T3 might interfere with the differentiation program of preneoplastic hepatocytes by inducing retrodifferentiation of the nodular hepatocytes to normal appearing cells via loss of their "resistant" phenotype, a rearrangement to single-cell plates, and an integration into the organizational pattern of the surrounding liver. Irrespective of the mechanism responsible for the anticarcinogenic effect of T3, it is of interest to note that hepatic amphophilic lesions induced by intraportal transplantation of thyroid follicles (14) , unlike focal lesions that developed following transplantation of pancreatic islands or ovarian tissue (13, 21) , did not progress to hepatocellular neoplasm.
A second important result obtained from this study is that CIPRO, unlike T3, does not exert any antitumoral effect. CIPRO, similar to T3, is an inducer of peroxisome proliferation and they both act via receptors of the superfamily of steroid/thyroid nuclear receptors on some common target Rats initiated with DENA were then subjected to the R-H model to generate GSTPpositive hyperplastic nodules. Five weeks after 2-AAF release (9 weeks after DENA), rats were subjected to 11 cycles of T3 or CIPRO. Rats were sacrificed at the end of the last cycle (13.5 months after initiation).
genes (4, 6, 20, 26) . Indeed, alterations induced by T3, such as an increase in activities of cytochrome oxidase, malic enzyme, glucose-6-phosphatase, and the decrease of glycogen phosphorylase and synthetase have also been observed in phenotypically altered hepatocyte foci induced by PPs (2, 27) . Moreover, both CIPRO and T3 are so-called direct mitogens, namely agents that induce hepatocyte proliferation without preceding cell loss (10) . Based on this premise, we aimed at determining whether CIPRO, administered with a similar protocol as T3, would exert an effect similar to that of thyroid hormone in negatively regulating the progression of hepatic nodules to HCC. The present results, however, showed that this member of the PPs family, unlike T3, does not possess any inhibitory effect on liver cancer induced by genotoxic agents. At the present the reason for the different effect of T3 and CIPRO on development of HCC is not known. It is tempting to speculate that in spite of the fact that T3 and CIPRO share several common properties including a powerful mitogenic activity, the latter compound lacks the capacity of inducing genes involved in the redifferentiation program likely to be responsible for the regression of hepatic nodules and lately the inhibition of HCC development caused by thyroid hormone.
